Biochemistry of Collagens, Laminins and Elastin: Structure, Function and Biomarkers

— —

Morten Karsdal (CEO, Nordic Bioscience A/S, Herlev, Denmark)

Biochemistry of Collagens, Laminins and Elastin

Structure, Function and Biomarkers

Morten Karsdal (CEO, Nordic Bioscience A/S, Herlev, Denmark)

$152.95

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Academic Press Inc
15 August 2016

Xenobiotics; Molecular biology

Biochemistry of Collagens, Laminins, and Elastin: Structure, Function, and Biomarkers provides a comprehensive introduction to collagen and structural proteins. Type I collagen is one of the most abundant molecules in the body, playing essential roles in different tissues, particularly bone and skin. A key aspect of type I collagen is its post-translational modifications which are essential for correct synthesis and structural integrity of collagens, for tissue-specific functionality, as well as for application as biomarkers of different pathologies.

This volume summarizes current data on key structural proteins (collagens, laminins and elastin), reviews how these molecules affect pathologies, and describes selected modifications of proteins that result in altered signaling properties of the original extracellular matrix component. Further, it discusses the novel concept that an increasing number of components of the ECM harbor cryptic signaling functions that may be viewed as endocrine functions. Additionally, it highlights how this knowledge can be exploited to modulate fibrotic disease.

By: Morten Karsdal (CEO Nordic Bioscience A/S Herlev Denmark)
Imprint: Academic Press Inc
Country of Publication: United States
Dimensions: Height: 229mm, Width: 151mm, Spine: 15mm
Weight: 430g
ISBN: 9780128098479
ISBN 10: 0128098473
Pages: 272
Publication Date: 15 August 2016
Audience: Professional and scholarly , Undergraduate
Replaced By: 9780128170687
Format: Paperback
Publisher's Status: Active

Chapter 1. Type I Collagen Chapter 2. Type II Collagen Chapter 3. Type III Collagen Chapter 4. Type IV Collagen Chapter 5. Type V Collagen Chapter 6. Type VI Collagen Chapter 7. Type VII Collagen Chapter 8. Type VIII Collagen Chapter 9. Type IX Collagen Chapter 10. Type X Collagen Chapter 11. Type XI Collagen Chapter 12. Type XII Collagen Chapter 13. Type XIII Collagen Chapter 14. Type XIV Collagen Chapter 15. Type XV Collagen Chapter 16. Type XVI Collagen Chapter 17. Type XVII Collagen Chapter 18. Type XVIII Collagen Chapter 19. Type XIX Collagen Chapter 20. Type XX Collagen Chapter 21. Type XXI Collagen Chapter 22. Type XXII Collagen Chapter 23. Type XXIII Collagen Chapter 24. Type XXIV Collagen Chapter 25. Type XXV Collagen Chapter 26. Type XXVI Collagen Chapter 27. Type XXVII Collagen Chapter 28. Type XXVIII Collagen Chapter 29. Laminins Chapter 30. Elastin Chapter 31. Structural Biomarkers

Morten Karsdal has been CEO of Nordic Bioscience A/S since June 2010. Since 2002, Morten Karsdal has focused his research on the discovery and development of novel biochemical markers. This has resulted in the development of more than 15 ELISA assays for detecting biomarkers that have been used for research in the fields of fibrosis, osteoporosis and osteoarthritis. One of these assays has been 510(k) approved by the Food and Drug Administration (FDA) in the USA.